These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28254765)

  • 1. Biological therapies in nonsmall cell lung cancer.
    Zugazagoitia J; Molina-Pinelo S; Lopez-Rios F; Paz-Ares L
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28254765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.
    Shroff GS; de Groot PM; Papadimitrakopoulou VA; Truong MT; Carter BW
    Radiol Clin North Am; 2018 May; 56(3):485-495. PubMed ID: 29622080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
    Gomes F; Tay R; Chiramel J; Califano R
    Drugs Aging; 2018 Sep; 35(9):819-834. PubMed ID: 30105645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update 2020: Management of Non-Small Cell Lung Cancer.
    Alexander M; Kim SY; Cheng H
    Lung; 2020 Dec; 198(6):897-907. PubMed ID: 33175991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
    Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
    Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge.
    Su C; Zhou F; Shen J; Zhao J; O'Brien M
    Eur J Cancer; 2017 Sep; 83():266-278. PubMed ID: 28763691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
    Huber RM; Reck M; Thomas M
    Eur Respir J; 2013 Oct; 42(4):1119-33. PubMed ID: 23429914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).
    McCarthy F; Roshani R; Steele J; Hagemann T
    J Leukoc Biol; 2013 Dec; 94(6):1201-6. PubMed ID: 23695306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
    Fitzgerald K; Simone CB
    Thorac Surg Clin; 2020 May; 30(2):221-239. PubMed ID: 32327181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Lung Cancer.
    Stinchcombe TE
    Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New biological agents in the treatment of advanced non-small cell lung cancer.
    Morrow PK; Kim ES
    Semin Respir Crit Care Med; 2005 Jun; 26(3):323-32. PubMed ID: 16052434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Lim SM; Syn NL; Cho BC; Soo RA
    Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
    Saito M; Suzuki H; Kono K; Takenoshita S; Kohno T
    Surg Today; 2018 Jan; 48(1):1-8. PubMed ID: 28280984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developments in targeted therapy & immunotherapy-how non-small cell lung cancer management will change in the next decade: a narrative review.
    Li MSC; Mok KKS; Mok TSK
    Ann Transl Med; 2023 Aug; 11(10):358. PubMed ID: 37675321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.